26th August 2022

Subject: Proceedings of the 86th Annual General Meeting of the Company

Dear Sir/Madam,

We hereby notify that the 86th Annual General Meeting (AGM) of the Company was held on Friday, 26th August 2022 at 3.00 pm through video conferencing / other audio-visual means (OAVM).

Pursuant to the provisions of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 we are enclosing the following:

1. Speech by Dr Y K Hamied – Chairman
2. Presentation by Mr Umang Vohra – Managing Director and Global Chief Executive Officer
3. Proceedings of the AGM.

Kindly take the above on record.

Thanking you,

Yours faithfully,

Rajendra Chopra
Company Secretary

Enclosed: a/a

Prepared by: Raviraj Soni
Eighty-Sixth Annual General Meeting  
Friday, 26th August 2022  
Address by Dr. Y. K. Hamied Chairman

Ladies & Gentleman,

I would like to welcome you to the 86th Annual General Meeting of your Company. Once again, this meeting is virtual. It has been two years since we last held an in-person meeting. Unfortunately, the unpredictable nature of the COVID-19 pandemic still prevails and now there is a new threat to public health with the monkeypox outbreak. I sincerely appeal to all of you to be disciplined and look after yourself, your families, your friends and colleagues as best possible.

Apart from this, the world continues to be plagued by newer diseases, war, supply chain disruptions, market volatility and above all, the major threats of climate change and anti-microbial resistance. Despite these major problems, scientists have been able to effectively control the COVID virus and its variants and also provide the world with newer therapies, diagnostics, vaccines and medications.

All of you have received by email a copy of Cipla’s annual report for the year ended 31st March 2022. This includes a detailed survey of your Company’s financial performance, management discussions and analysis, business strategy, technical and manufacturing operations, human relations, corporate social responsibility, supply chain management and overall company governance. With your permission, I take this report as read. It is the 5th year in succession that your Company has presented a fully integrated annual report and the people responsible for it have to be duly commended.

You would be interested to know that today, India is among the largest providers of generic medicines in the world, catering to 20% of the global demand in terms of volume. India ranks 3rd globally by pharma volume and 14th by value and has the highest number of approved pharmaceutical plants outside the USA. The pharma industry has to navigate uncertainties. Building innovation, both incremental and transformational with scientific acumen is the only way to progress.

The year under review has been a momentous one for Cipla. We were recognised by Business Standard as the ‘Company of the year 2021’ and our executive Vice-Chairperson, Samina Hamied, was conferred with The Economic Times ‘Businesswoman of the Year’ 2021 award. Cipla was also recognized among the companies responsible for India’s overall development covering 75 years of independence. These recognitions are a testament to the high standards and commitment of all Cipla employees who continue to uphold the Company’s legacy of Caring for Life.
At this stage, I would again like to thank all in the Cipla family throughout India and globally for their outstanding performance and work during this difficult year, not only in fighting COVID-19, but also in providing medicines on a continuous basis worldwide. The work done has been well beyond the call of duty and your Company has been among the most responsible in the industry during this period. We have made significant progress in our business and continue our forward growth, not only in India, but also in the USA and other key markets. Cipla continues to remain the third largest pharmaceutical company, both in India and in South Africa. Globally, among all pharmaceutical companies we rank number 52 and among the global generic drug companies we rank in the leading 15. We have expanded our leadership role beyond providing medicines and are on a path to becoming an overall healthcare provider, thereby improving the quality of life of patients.

It is now 25 years since we started the Cipla Palliative Care and Training Centre in Pune. This humanitarian institution provides free-of-cost services to all patients who are terminally ill with serious medical problems, in particular cancer and allied ailments. It supports both patients and their families during critical and difficult times. We are proud that this institution is unique, and one of its kind not only in India, but elsewhere as well.

I would like to reiterate that Cipla continues to be a partner of choice for many domestic and global pharmaceutical companies. We have an excellent on-going relationship with international organisations such as the Global Fund, DNDi, MMV, UNAIDS, CHAI, etc. Within India, Cipla has close links with Government institutions and laboratories under ICMR, CSIR and establishments such as CDRI, IICT, etc., as also private organisations and universities. These partnerships help us in R&D, manufacturing and distribution of specialized medicines and diagnostics.

Finally, I would like to assure you, our shareholders, that your Company will continue to do whatever best possible towards healthcare, with a humanitarian approach by providing affordable medication and that none should be denied treatment, both in India and globally. My sincere gratitude to all my colleagues on the Cipla Board of Directors and the Company’s leadership team headed by Samina Hamied and Umang Vohra for their support, guidance and visionary leadership. I also wish to acknowledge the contribution of all our employees, both past and present, as also our partners and collaborators in bringing Cipla to its current eminent position in the pharma industry and ensuring the future success of your Company. As always, our profuse thanks to our shareholders, medical profession, customers, suppliers, partners, associates for their continuing support and trust in our Company. Many thanks for being with us today virtually in such large numbers.

Thank you.
MD & GCEO’s Address

Umang Vohra
Aug 2022
## Cipla – FY22 Performance

We delivered strong performance across our key markets; upward operating profitability trajectory sustained

### Overall Cipla

<table>
<thead>
<tr>
<th></th>
<th>Revenue (YoY Growth in INR terms)</th>
<th>EBITDA Margin</th>
<th>R&amp;D Spends (YoY Growth)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall</td>
<td>14%</td>
<td>21%</td>
<td>21%</td>
</tr>
<tr>
<td>Ex-covid</td>
<td>12%</td>
<td>~22%</td>
<td></td>
</tr>
</tbody>
</table>

*Note: 1. Excludes impact of one-time covid inventory and other charges of ~ INR 200cr in Q4 | 2. Opex including depreciation*

### One-India

- **One India (YoY Growth in INR terms)**: 27%
  - Prescription business crossing $1Bn scale; continued traction in trade generics and consumer health

### North America

- **NA revenue (YoY Growth)**: $594Mn, 8%
  - Continued momentum in respiratory franchise and peptide unlocking

### SAGA

- **International Markets & API (YoY Growth in $ terms)**
  - **International Markets**: $385Mn
  - **API**: 5%
  - Strong respiratory filings in Europe

- **SA Private (YoY Growth in ZAR terms)**: 15%
  - Market beating growth in private business on steady launches
Cipla Foundation works across the four focus areas of Health, Education, Skilling and Disaster Response in India and South Africa.
At Cipla, we believe that when purpose meets passion, people and planet are the winners.

**FY25 Goals**

<table>
<thead>
<tr>
<th>Goals 2025</th>
<th>FY2022 Progress</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Carbon Neutrality</strong></td>
<td></td>
</tr>
<tr>
<td>Renewable energy</td>
<td>Carbon Neutrality</td>
</tr>
<tr>
<td>GHG Reduction</td>
<td>Water Neutrality</td>
</tr>
<tr>
<td>24%</td>
<td>Zero Liquid Discharge pl</td>
</tr>
<tr>
<td>16%</td>
<td>3 formulation sites commissioned</td>
</tr>
<tr>
<td><strong>Water Neutrality</strong></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>120,648 kl</td>
</tr>
<tr>
<td>42%</td>
<td>Rain water harvesting potential</td>
</tr>
<tr>
<td><strong>Zero Waste to Landfill</strong></td>
<td>Total water recycled/reused</td>
</tr>
<tr>
<td>2/3rd</td>
<td>0.53</td>
</tr>
<tr>
<td>30%</td>
<td>Total Incident Rate</td>
</tr>
<tr>
<td>100%</td>
<td>Well-being of Employees and Par</td>
</tr>
<tr>
<td>Equivalent post-consumer plastic waste collected and channelized to authorized recycling vendor</td>
<td>partners</td>
</tr>
</tbody>
</table>

**AMR Stewardship**
Achieved a score of 60% in generic pharma manufacturing in Access to Medicine Foundation’s AMR Benchmark Report 2021, 2nd highest in Indian Generic Pharma companies.

**Green Chemistry and Making it Right**
- Eliminated 7 undesirable solvents
- Substituted 3 solvents with safer alternatives
- 112 HAZOP studies conducted during the year.

**Sustainability Award Industry Mover 2022**

**S&P Global**
Cipla - Strategy strengthened for a Sustainable tomorrow

Our strategic Business objectives to drive growth, and deliver pioneering and innovative healthcare solutions

Lung Leadership
Become a global lung leader across the care continuum
Innovative Drug device play -
Market leader in respules, DPI and MDI across key markets -
Digital initiatives for lifestyle support -

AMR
Build Novel Product portfolio of Anti-infectives for resistant infections

Wellness
Build a Global consumer wellness franchise

Strengthen Home markets
Continue to build scale and depth in home markets

Scale Specialty
Focus on complex generics, peptides and respiratory-related products

Unlock Emerging markets
Build deeper markets and drive sustainable growth

Leverage Digital
Focus on Digital and patient centricity as future pivots for Business models

Continuous Improvement
Adopting Technology to improve efficiency and Unlock capacity

Quality 4.0
Shift in Quality paradigm; Led by Culture and Automation

Talent and Manning Model
Strengthen the talent pipeline, improve productivity and happiness quotient
Cipla of the Future
Pioneering, Innovative and Firmly rooted in Care

Our Purpose, our true North

“Never again will India be starved of essential drugs
- Dr. K. A. Hamied
(1898 - 1972)
Founder, Cipla”

Innovation key driver for future

- Biosimilars
- mRNA
- Global Wellness Franchise
- Digital outreach
- Respiratory Leaders: Drug device + Bio Drugs
- Diagnostics
- Industry 4.0

Sustainable Future

- Championing Climate Positivity
- Accelerating Community Well-Being
- Raising the Bar on Governance
- Enhancing Access and Affordability

A Momentous Year

- Cipla conferred BS Company of the Year Award
- Cipla, Only Indian Pharma Player to secure a rank
- Cipla conferred Best Governed Company Award
- Cipla conferred ‘FICCI CSR Award’
- Cipla recognized ‘Top Employer for 2022 in SA’

"Forbes World’s Best Employers 2021"
Thank You!
Summary of proceedings of the 86th Annual General Meeting

The 86th Annual General Meeting (AGM) of the Members of Cipla Limited (the “Company”) was held on Friday, 26th August 2022, through video conferencing (VC) / OAVM. In compliance with the SEBI (Listing Obligations and Disclosure Requirements) Regulations, the webcast facility was also provided to the shareholders. The AGM commenced at 3.00 p.m. IST and concluded at 5.15 p.m. IST.

Directors present through VC:

1) Dr Y K Hamied – Chairman
2) Mr Adil Zainulbhai – Lead Independent Director
3) Mr Ashok Sinha – Independent Director and Chairman – Audit Committee
4) Mr M K Hamied – Vice-Chairman and Chairman - Corporate Social Responsibility Committee
5) Dr Mandar Vaidya – Independent Director
6) Dr Peter Mugyenyi – Independent Director
7) Ms Punita Lal – Independent Director and Chairperson – Nomination and Remuneration Committee
8) Mr P R Ramesh – Independent Director
9) Mr Robert Stewart – Independent Director
10) Ms Samina Hamied – Executive Vice-Chairperson and Chairperson – Investment and Risk Management Committee
11) Mr S Radhakrishnan – Non-executive Director and Chairperson – Stakeholders Relationship Committee
12) Mr Umang Vohra – Managing Director and Global Chief Executive Officer

In attendance through VC:

1) Mr. Ashish Adukia – Global Chief Financial Officer
2) Mr Rajendra Chopra – Company Secretary
3) Mr Ashish Gupta – Representative of Walker Chandiok & Co LLP, Chartered Accountants, Statutory Auditor
4) Mr B. Narasimhan – Practising Company Secretary, representative of BNP & Associates, Secretarial Auditor and the scrutiniser for the purpose of remote e-voting and voting at the AGM
5) Mr D H Zaveri – Cost Auditor

Shareholders present through VC / Other audio-visual means: 113

Pursuant to Article 77 of Article of Association of the Company, Dr Y K Hamied, Chairman presided over the meeting and welcomed the shareholders. The Chairman introduced the directors, management team, statutory auditor, secretarial auditor, cost auditor and assurance reviewer participating through VC / OAVM. Requisite quorum being present, the Chairman called the meeting to order and requested Mr Rajendra Chopra, Company Secretary to make the statutory announcements.
The Company Secretary *inter-alia* informed the shareholders that,

a) the meeting was being held through VC / OAVM in accordance with the provisions of Companies Act, 2013 and various circulars issued by the Ministry of Corporate Affairs (MCA) and the Securities and Exchange Board of India (SEBI).

b) the Integrated Annual Report containing the financial statements, board’s report, auditor’s report, and other reports along with notice of this meeting were already circulated to the members at their registered email address and taken as read.

c) since there were no qualifications, observations, comments or remarks in the statutory auditor’s and the secretarial auditor’s reports for the year ended 31\textsuperscript{st} March 2022, the reports were taken as read.

d) the remote e-voting facility commenced at 9.00 a.m. (IST) on Monday, 22\textsuperscript{nd} August 2022, and ended at 5.00 p.m. (IST) on Thursday, 25\textsuperscript{th} August 2022. The voting rights were reckoned on the shares held as on the cut-off date i.e. 19\textsuperscript{th} August, 2022.

e) electronic voting facility during the AGM was made available for members who had not exercised their vote through remote e-voting facility and was open up to 30 minutes from the conclusion of the meeting.

f) the statutory documents and reports as required to be placed at the AGM were open for inspection electronically.

The Chairman addressed the shareholders and delivered his speech. The Chairman apprised the shareholders on the Company’s progress. Thereafter, Mr. Umang Vohra, Managing Director and Global Chief Executive Officer, was invited to brief the shareholders on the operations and performance of the Company.

Mr. Umang Vohra made a brief presentation covering the FY22 performance, CSR initiatives, ESG FY25 goals and progress during the year, Strategy, focus areas for the future, and awards and recognition.

With the permission of the Chairman, the Company Secretary explained to the shareholders the resolutions put forth for approval. He stated that since the meeting was held through VC and the resolutions provided in the notice were being put to vote through e-voting, there would be no proposing and seconding of the resolutions.

The summary of the resolutions put up for shareholder’s approval were as under:

<table>
<thead>
<tr>
<th>Sr. No.</th>
<th>Agenda Item</th>
<th>Type of Resolution</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>To receive, consider and adopt the audited standalone financial statements of the Company for the financial year ended 31\textsuperscript{st} March 2022 and the reports of the Board of Directors and Auditor thereon</td>
<td>Ordinary</td>
</tr>
<tr>
<td>2.</td>
<td>To receive, consider and adopt the audited consolidated financial statements of the Company for the financial year ended 31\textsuperscript{st} March 2022 and the report of the Auditor thereon</td>
<td>Ordinary</td>
</tr>
<tr>
<td>3.</td>
<td>To declare final dividend on equity shares</td>
<td>Ordinary</td>
</tr>
<tr>
<td>4.</td>
<td>To re-appoint Ms Samina Hamied as director liable to retire by rotation*</td>
<td>Ordinary</td>
</tr>
<tr>
<td>5.</td>
<td>To appoint Dr Mandar Purushottam Vaidya as independent director</td>
<td>Special</td>
</tr>
</tbody>
</table>
The Chairman then invited queries from the shareholders which were suitably replied by Mr Umang Vohra, Managing Director and Global Chief Executive Officer. Thereafter, the Chairman announced the commencement of e-voting at the AGM and requested Mr B. Narasimhan, the scrutiniser, for the orderly conduct of the e-voting.

The Company Secretary was authorised to receive the scrutiniser’s report and announce the e-voting results.

The Chairman thanked the shareholders for attending the 86th AGM of the Company and declared the meeting as concluded.

As per the scrutiniser’s report received, all the resolutions as set out in the notice of the 86th AGM were declared as approved with the requisite majority.

Thanking you,

Yours faithfully,
For Cipla Limited

Rajendra Chopra
Company Secretary

Prepared by: RaviRaj Soni